Idexx Laboratories price target raised to $775 from $700 at Stifel

Stifel analyst Jonathan Block raised the firm’s price target on Idexx Laboratories (IDXX) to $775 from $700 and keeps a Buy rating on the shares. The firm says that its upgrade thesis from last week was that visits get modestly better, a soft landing occurs with price, and the “IDEXX premium” continues to strengthen. This should allow CAG Dx recurring revenue growth to accelerate in 2026/2027, which Stifel believes will support the stock’s multiple at current levels. These variables all played out in the quarter as visits and the “premium” improved, and price has proved somewhat durable, the firm argues.